-
- Padmanee Sharma
- Department of Immunology, M.D. Anderson Cancer Center, Houston, TX, USA.
-
- James P. Allison
- Department of Immunology, M.D. Anderson Cancer Center, Houston, TX, USA.
説明
<jats:p>Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.</jats:p>
収録刊行物
-
- Science
-
Science 348 (6230), 56-61, 2015-04-03
American Association for the Advancement of Science (AAAS)